ReviewJournal of fungi (Basel, Switzerland)2022
Current Landscape of Coccidioidomycosis.
Review in Journal of fungi (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- A Clinical Prediction Model for Invasive Pulmonary Fungal Disease in Dialysis Patients: Development, Validation, and Pharmacist-Led Application.Infection and drug resistance · 2026Article
- First Reports of Canine Coccidioidomycosis in the Paso del Norte Region, Mexico-USA: A 10-Case Series.Veterinary medicine and science · 2025Article
- Suspected Acute Pulmonary Coccidioidomycosis in Traveler Returning to Switzerland from Peru.Emerging infectious diseases · 2024Article
- Review
- Clinical Characteristics and Mortality Risks Among Patients With Culture-Proven Coccidioidomycosis Who Are Critically Ill: A Multicenter Study in an Endemic Region.Open forum infectious diseases · 2024Article
- Coccidioidomycosis in Immunocompromised at a Non-Endemic Referral Center in Mexico.Journal of fungi (Basel, Switzerland) · 2024Article
- Challenges in the Long-term Management of Patients With Coccidioidal Meningitis: A Retrospective Analysis of Treatment and Outcomes.Open forum infectious diseases · 2023Article
- Diagnosis and Treatment of Pulmonary Coccidioidomycosis and Paracoccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2023Review
- Pathogenic Drug Resistant Fungi: A Review of Mitigation Strategies.International journal of molecular sciences · 2023Review
- Surgical Resection to Treat a Japanese Patient with Pulmonary Coccidioidomycosis.Infection and drug resistance · 2023Article
- Clinical Challenges of Emerging and Re-Emerging Yeast Infections in the Context of the COVID-19 Pandemic.Microorganisms · 2022Review
- Genomic Data Mining Reveals Abundant Uncharacterized Transporters inJournal of fungi (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Coccidioidomycosis, also known as Valley fever, is an endemic fungal infection commonly found in the southwestern parts of the United States. However, the disease has seen an increase in both in its area of residency and its prevalence. This review compiles some of the latest information on the epidemiology, current and in-development pharmaceutical approaches to treat the disease, trends and projections, diagnostic concerns, and the overlapping dynamics of coccidioidomycosis and COVID-19, including in special populations. This review provides an overview of the current diagnostic and therapeutic strategies and identifies areas of future development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.